Source: Livestream of White House Africa Cancer Care ForumThe White House Cancer Moonshot is committing an additional $100 million to programs focused on reducing cancer burden in African countries.
The Centers for Medicare and Medicaid Services said it intends to start providing additional reimbursement for some high-cost drugs for people with Medicare who receive care at Indian Health Service or tribal hospitals, beginning Jan. 1, 2025.
Robert C. Gallo joined Tampa General Hospital on July 8 as founder and director of the Microbial Oncology Program at the TGH Cancer Institute and senior scientific advisor to the executive director of the TGH Cancer Institute.
Jennifer Munson has been named director of the Fralin Biomedical Research Institute at VTC’s Cancer Research Center in Roanoke, VA.
Monica BertagnolliBrett GuthrieNIH Director Monica Bertagnolli and Rep. for Kentucky’s 2nd congressional district, Brett Guthrie were named recipients of Friends of Cancer Research 2024 Cancer Leadership Award.
The members of the American Society for Radiation Oncology recently elected five new officers to ASTRO’s board of directors.
Thyme Care announced the close of a $95 million capital raise. With $55 million in equity funding, Thyme Care welcomes new investor Concord Health Partners with participation from all existing investors, including CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital.
The phase III ARANOTE trial, investigating Nubeqa (darolutamide) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, has met its primary endpoint of radiological progression-free survival. Nubeqa plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT.
A Hologic-commissioned survey from Gallup reveals that while most women across the United States understand the significance of regular health screenings, an estimated 72 million have missed or postponed a recommended screening.
Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, research suggests, which could contribute to higher rates of aggressive prostate cancer in African American men.
